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SP1049C is a novel anticancer agent containing doxorubicin and two nonionic pluronic block copolymers. In preclinical studies,
SP1049C demonstrated increased efficacy compared to doxorubicin. The objectives of this first phase I study were to determine the
toxicity profile, dose-limiting toxicity, maximum tolerated dose and pharmacokinetic profile of SP1049C, and to document any
antitumour activity. The starting dose was 5mgm
 2 (doxorubicin content) as an intravenous infusion once every 3 weeks for up to
six cycles. A total of 26 patients received 78 courses at seven dose levels. The dose-limiting toxicity was myelosuppression and DLT
was reached at 90mgm
 2. The maximum tolerated dose was 70mgm
 2 and is recommended for future trials. The pharmacokinetic
profile of SP1049C showed a slower clearance than has been reported for conventional doxorubicin. Evidence of antitumour activity
was seen in some patients with advanced resistant solid tumours. Phase II trials with this agent are now warranted to further define its
antitumour activity and safety profile.
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Doxorubicin is one of the most widely used and active anticancer
agents. Its clinical usefulness is limited by inherent or induced
drug resistance and by toxicity considerations. Several approaches
have been used to try and improve the therapeutic efficacy and
toxicity profile of doxorubicin including the development of
anthracycline analogues and the incorporation of anthracyclines
into drug delivery vehicles, such as liposomes and polymeric
drug conjugates (Ranson et al, 1997; Vasey et al, 1999). SP1049C
represents a novel approach in which doxorubicin is formulated
with two nonionic pluronic block copolymers, Pluronic L61 and
Pluronic F127 (Figure 1) (Collet, 2003). Doxorubicin is noncova-
lently incorporated into micelles with the block copolymers, and in
standard XTT in vitro cytotoxicity assays (Venne et al, 1996),
SP1049C exhibits greater efficacy than doxorubicin against a
variety of drug-resistant tumour cell lines. This improved efficacy
of SP1049C in vitro appears to be due to increase in cellular drug
influx, inhibition of energy-dependent drug efflux and changes in
intracellular drug trafficking (Venne et al, 1996). Compared to
doxorubicin, SP1049C demonstrated superior antitumour activity
in vivo in multiple animal tumour models and activity in
doxorubicin-resistant settings (Batrakova et al, 1996; Alakhov
et al, 1999). The plasma pharmacokinetics and tissue distribution
of doxorubicin when administered as SP1049C have been studied
in normal and tumour-bearing mice. Increased tissue area under
the curves (AUC) were seen in tumour and brain with SP1049C
compared to those seen with equivalent doses of free doxorubicin.
Area under the curves and maximal tissue concentrations were
similar for SP1049C and free doxorubicin in liver, kidney, heart,
lung and plasma. SP1049C exhibited similar toxicology to
conventional doxorubicin in toxicology studies in mice and rats
(Alakhov et al, 1999).
This is the first clinical trial of SP1049C. The primary objectives
were to determine the toxicity profile, dose-limiting toxicity (DLT),
maximum-tolerated dose (MTD) and pharmacokinetic profile of
SP1049C. The secondary objective was to evaluate the antitumour
effects of SP1049C in patients with advanced cancer.
PATIENTS AND METHODS
Inclusion and exclusion criteria
Patients with histologically proven cancer refractory to conven-
tional treatment or for which no suitable conventional therapy
existed were considered for entry into this study. Patients were
required to be X18 years of age with a Karnofsky Performance
Status of 80 or greater and an expected survival of 12 weeks
or more. They needed adequate haematological and biochemical
function with haemoglobin X10.0gdl
 1, total white blood cells (WBC)
X3.0 10
9l
 1, absolute neutrophil count (ANC) X2.0 10
9l
 1
and platelets X100 10
9l
 1, and serum creatinine p130mmoll
 1
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l(if 4130mmoll
 1 then creatinine clearance must be 450mlmin
 1),
serum bilirubin p20mmoll
 1, serum AST or ALT p2 upper
limit of the normal. A left ventricular ejection fraction (LVEF)
X55% by multinucleated gated angiography (MUGA) was also
required.
Patients were excluded if they fulfilled any of the following:
major thoracic or abdominal surgery in the preceding 4 weeks;
chemotherapeutic agents, experimental drugs or radiation therapy
(other than local radiotherapy not involving bone marrow
reserves) within the 4 weeks prior to therapy; mitomycin C or
nitrosoureas within the previous 6 weeks; any persistent toxic
manifestations of previous treatments (except alopecia) must have
resolved, or be no greater than Grade 1 and have been stable for
over 4 weeks prior to entry; active uncontrolled infection, or other
significant nonmalignant intercurrent illness; pregnant or lactating
women (negative serum pregnancy test prior to enrolment in those
women with child-bearing potential and all patients were required
to use medically approved contraceptive precautions during the
study and for 4 weeks afterwards); known or suggested central
nervous system metastases; known hypersensitivity to anthracy-
cline therapy; prior radiotherapy to more than one-third of
haemopoietic sites; clinically significant hepatic disease other than
involvement by tumour; history of cardiac disease with New York
State Heart Association Class II level or greater or myocardial
infarction within the past year; any other condition which in
the Investigator’s opinion would not make the patient a good
candidate for the study.
The study was conducted under the auspices of the Cancer
Research Campaign (now Cancer Research UK) in accordance with
the principles of the International Conference on Harmonisation
of Good Clinical Practice (ICH-GCP) guidelines and the Declara-
tion of Helsinki. The trial protocol was approved by the Local
Research Ethics Committee covering each trial centre and all
patients gave informed written consent.
Treatment
SP1049C carrier solution was supplied by Supratek Pharma Inc.
(Canada) in 100ml vials containing Pluronic L61 (0.25%wv
 1)
and Pluronic F127 (2%wv
 1) in 0.9% sodium chloride for
injection. Doxorubicin hydrochloride from Pharmacia Upjohn
was provided in 10 and 50mg vials. In total, 25ml (or 5ml for
smaller doses) of SP1049C carrier solution for intravenous (i.v.)
injection was used to reconstitute 50mg (or 10mg for smaller
doses) vials of doxorubicin hydrochloride under aseptic conditions
to provide a solution of doxorubicin hydrochloride 2.0mgml
 1 in
carrier solution. The reconstituted SP1049C contained 2.0mgml
 1
doxorubicin hydrochloride, 2.5mgml
 1 Pluronic L61 and
20mgml
 1 Pluronic F127 in 0.9% sodium chloride. The pluronic
carrier solution and reconstituted SP1049C were stored at 41C.
Reconstituted SP1049C stored at 41C was used within 24h of
reconstitution.
SP1049C was administered via a peripheral i.v. cannula at a rate
of 2mlmin
 1. The starting dose (expressed as doxorubicin
content) was 5mgm
 2, which was approximately a tenth of the
MTD in the mouse and rat toxicology studies. An i.v. infusion
of SP1049C was given once every 3 weeks for a maximum of
six cycles.
Toxicity and response evaluation
Pretreatment evaluation included a complete medical history and
physical examination as well as full blood count, biochemical
profile, routine urinalysis, 12-lead electrocardiogram (ECG) and
MUGA. Female subjects with child-bearing potential also under-
went a pregnancy test. A baseline chest radiograph and appro-
priate radiology to evaluate the disease were performed. Tumour
markers were also measured if applicable.
Safety was evaluated by recording signs and symptoms during
the study period, monitoring vital signs, urinalysis, ECG, MUGA
(at baseline, after every two courses and at withdrawal) and
laboratory tests (haematological and biochemical). All toxicities
were graded according to the National Cancer Institute Common
Toxicity Criteria Version 2 (NCI, 1998) and were assessed weekly
and at the end of each cycle of SP1049C. Dose-limiting toxicities
were defined as any of the following events: (1) two out of six (or
X30%) patients experienced Grade 4 neutropenia lasting 45 days
or if associated with fever, (2) two out of six (or X30%) patients
experienced Grade 4 thrombocytopenia, (3) two out of six (or
X30%) patients had Grade 3 or Grade 4 nonhaematological
toxicity (excluding Grade 3 nausea and vomiting in patients who
have not received optimal treatment with antiemetics), (4) drug-
related death. The MTD was defined as the dose level of SP1049C
below that at which 30% or more of the patient population
experience DLT due to SP1049C. The MTD was to be the dose
recommended for phase II studies. Patients were to be followed up
until 4 weeks after the last administration of SP1049C. Response
was assessed using WHO response criteria (WHO, 1979) at
baseline, after every two cycles and after withdrawal. The duration
of response was defined as the interval from the date of first
treatment to the date of documented disease progression.
Dose escalation
It was planned that cohorts of patients would be treated with
SP1049C at 5, 10, 20, 35, 50, 70 and 90mgm
 2 (expressed as
doxorubicin content). At the first three dose levels (5, 10 and
20mgm
 2) if no toxicity greater than Grade 1 was encountered
during the first cycle of SP1049C in the first patient at that level,
then subsequent patients could enter at the next dose level at the
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Figure 1 Structures of (A) doxorubicin (B) block copolymers.
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ldiscretion of the investigators. At other dose levels, a total of three
patients had to complete 21 days on study before a decision to dose
escalate was made. If a patient withdrew from treatment before day
22 of SP1049C, then this patient was replaced. If DLT was not
reached at the seventh dose level of 90mgm
 2, further dose
increments would be in steps of 20–25% above the prior dose
level. If one instance of DLT was observed in three patients, then
the dose level would be expanded and an additional three patients
treated at that dose level. If one out of six patients experienced
DLT, dose escalation would continue. If two out of six patients
experienced DLT, three more patients would be treated at a lower
dose. This lower dose level would be defined as the MTD unless
two out of six patients at that dose level developed DLT, in which
case further dose reduction would be made. Patients were assigned
to a dose level at the time of enrolment. Intrapatient dose
escalation was not permitted.
Treatment delay or dose modification
A treatment delay of up to 3 weeks was allowed for resolution of
DRT. If a patient who had shown clinical benefit from SP1049C
developed a DLT, SP1049C could be continued at a lower dose
level, up to a maximum of six cycles (in total), at the discretion of
the Investigator.
Patients could be withdrawn from the study for any of the
following reasons: progressive disease; unacceptable toxicity;
cardiac ejection fraction o50% or fall of X15% from baseline;
serious adverse event requiring discontinuation of study drug
treatment; serious violation of the study drug protocol (including
persistent patient attendance failure and noncompliance); with-
drawal of consent (if a patient had been in the study for less
than 22 days, then an additional patient would be recruited to
replace them); any unforeseen event or clinical reason which the
investigator felt made further treatment inadvisable.
Pharmacokinetics
With the first dose of SP1049C, venous blood samples were drawn
for assay of doxorubicin concentrations as follows: predose, on
completion of infusion and at 5, 10, 20 and 40min, and at 1, 2, 4, 8,
24, 48, 72 and 96h after the infusion. Samples of venous blood
(7–9ml) were drawn into heparinised sample tubes from a
site separate from the drug administration site. Samples were
centrifuged within 20min of collection at 2000g for 20min and the
plasma was transferred into an appropriately labelled polypropy-
lene tube and stored frozen and protected from light at  701C
until analysis. In the absence of sensitive methods for the analysis
of free vs pluronic-associated doxorubicin, the determination of
plasma concentrations of total doxorubicin was performed by
reverse-phase high-performance liquid chromatography (HPLC)
following extraction of doxorubicin from plasma. Briefly, standard
curves of doxorubicin alone and SP1049C were prepared covering
1–500ngml
 1. Two patient plasma samples obtained 10min
postinfusion were used as internal controls in each analysis run.
Within run and between run coefficients of variation were o10%
and typically less than 5%. The lower limit of detection was
0.5ngml
 1 with lower limit of quantitation of 1ngml
 1. Stan-
dards, internal control and patient samples (500ml) were extracted
with 1ml methanol/50ml 20% citric acid and assayed by HPLC
with fluorescence detection (Bronchud et al, 1990).
Analysis
Adverse events were graded according to CTC Criteria Version 2.
Tumour response was defined according to WHO criteria.
Pharmacokinetic analysis was performed using ABBOTTBASE
pharmacokinetic systems software on plasma concentration time
point data for total doxorubicin for each patient. AUC extrapolated
to infinity (AUC0–N) of doxorubicin was calculated using the
trapezoidal rule for the sum of AUC to the last measured time
point and Cpred/lz, where Cpred is the predicted concentration at
the last measured time point and the terminal elimination rate
constant (lz) is derived from the final log linear phase of the
concentration time curve using least-squares regression analysis
with visual inspection of the data to determine the appropriate
number of data points to include in the calculation of lz, and the
goodness of fit was assessed by Akaike’s information criteria. Each
patient’s data was analysed by nonlinear least-squares regression
analysis to determine individual pharmacokinetic parameters.
RESULTS
Patient and tumour characteristics
A total of 26 patients were enrolled into the study and the baseline
demographics are shown in Table 1. The following dose levels were
evaluated: 5, 10, 20, 35, 50, 70 and 90mgm
 2. At the time of
analysis, all patients had completed SP1049C treatment. In all, 78
courses of treatment were administered at seven dose levels. At the
first three dose levels, one patient was treated per dose level as no
toxicity greater than grade 1 was observed. At subsequent dose
levels, cohorts of at least three patients were treated. Dose levels
were expanded when DLT was observed. A total of seven patients
were treated at 35mgm
 2 (including one patient who died before
day 22 of cycle 1), six patients at 50mgm
 2, seven patients at
70mgm
 2 (including one patient withdrawn before day 22 of cycle
1) and three patients at 90mgm
 2. In total, five patients received
six cycles of treatment; 20 stopped earlier because of disease
progression or treatment-related toxicity; one patient requested to
discontinue treatment.
Toxicity
All 26 patients were evaluable for toxicity. SP1049C showed a
predictable spectrum of toxicities at doses of 35mgm
 2 and above.
These included reversible, dose-related leucopenia, neutropenia
Table 1 Patient and tumour characteristics
No. of patients 26
Male/female 19/7
Median age, years (range) 52 (28–74)
Performance status (Karnofsky)
100 2
80/90 24
Primary tumour site
Colorectal 5
Oesophagus 5
Soft-tissue sarcoma 4
Lung 3
Mesothelioma 2
Others 7
a
Prior treatment
Surgery 26
Radiotherapy 6
Hormonal/biological 6
Chemotherapy 25
Prior chemotherapy
Median number of regimens (range) 2 (1–4)
Previous anthracycline treatment 9
aEwing’s sarcoma (one), ovary (one), kidney (one), cholangiocarcinoma (one), liver
(one), neuroblastoma (one), unknown primary (one).
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land stomatitis. In addition nausea/vomiting, fatigue and alopecia
were common drug-related adverse events. Four patients had
grade 2 decrease in LVEF. Overall, the spectrum of adverse events
was similar to that seen with conventional doxorubicin. No plantar
palmar erythrodysthesia was seen in any patient.
Haematological toxicity for each dose level is shown in Table 2.
The dose-limiting toxicity comprised myelosuppression and DLT
was reached at 90mgm
 2. The incidence of grade 3 or worse
neutropenia at below 35mgm
 2 was zero out of three patients, at
35mgm
 2 one out of seven patients, at 50mgm
 2 two out of six-
patients, at 70mgm
 2 four out of seven patients, at 90mgm
 2
three out of three patients. Neutropenia was seen at dose levels of
35–90mgm
 2 in 17 (65%) of patient with the nadir occurring
between days 8 and 15 postinfusion and with recovery to baseline
levels by day 22. Thrombocytopenia of grades 1–3 was seen from
dose levels 35–90mgm
 2 in 10 (38%) patients. Anaemia grades
1–3 was seen from dose levels 20–90mgm
 2 in 20 (77%) patients.
There was no grade 4 thrombocytopenia or anaemia at any dose
level.
SP1049C induced nonhaematological toxicity at each dose level
is shown in Table 3.
Cardiac Four patients had a grade 2 fall (420%) in their
LVEF. The total cumulative dose of anthracyclines (including
previous therapy) for these patients was as follows: 320mgm
 2
(SP1049C, doxorubicin and epirubicin), 210mgm
 2 (SP1049C
only), 440mgm
 2 (SP1049C and doxorubicin) and 870mgm
 2
(SP1049C and doxorubicin). In three of the four patients, there
were no changes in ECGs or clinical signs of cardiac impairment.
One patient who had received a total of 870mgm
 2, who had
normal LVEF during SP1049C therapy and had an LVEF at the end
of the study of 29%, died subsequent to trial completion during an
Table 2 Haematological toxicities (worst grade per patient)
Adverse
event
Dose level
(mgm
 2) Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Neutrophils 5 1 0000
1 0 10000
2 0 10000
3 5 41110
5 0 12111
7 0 10204
9 0 00003
Leucocytes
(WBC)
5 10000
1 0 10000
2 0 01000
3 5 41110
5 0 21111
7 0 11122
9 0 00012
Haemoglobin 5 1 0000
1 0 10000
2 0 01000
3 5 13210
5 0 12300
7 0 21400
9 0 01110
Platelets 5 1 0000
1 0 10000
2 0 10000
3 5 52000
5 0 32010
7 0 41110
9 0 11100
Table 3 Nonhaematological toxicities (worst grade per patient)
Adverse
event
Dose level
(mgm
 2) Grade 1 Grade 2 Grade 3 Grade 4
Nausea 5 0 0 0 NA
1 0 000 N A
2 0 010 N A
3 5 040 N A
5 0 221 N A
7 0 320 N A
9 0 010 N A
Stomatitis 5 0000
1 0 0000
2 0 0000
3 5 2100
5 0 1100
7 0 1310
9 0 0110
Vomiting 5 0000
1 0 0000
2 0 0000
3 5 1110
5 0 3000
7 0 1300
9 0 1100
Reduction in
LVEF
5 0000
1 0 0000
2 0 0000
3 5 1100
5 0 0000
7 0 1300
9 0 0000
Fatigue 5 0000
1 0 0000
2 0 0000
3 5 0100
5 0 0210
7 0 2400
9 0 2100
Alopecia 5 0 0 — —
10 0 0 — —
20 0 0 — —
35 2 1 — —
50 3 1 — —
70 1 4 — —
90 2 0 — —
Bilirubin 5 0000
1 0 0000
2 0 0000
3 5 0000
5 0 1000
7 0 0100
9 0 1000
AST/ALT 5 0000
1 0 0000
2 0 0000
3 5 1000
5 0 1100
7 0 1000
9 0 1100
NA¼not applicable. ALT¼alanine aminotransferase; AST¼aspartate aminotrans-
ferase; LVEF¼left ventricular ejection fraction.
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lepisode of sepsis. The impaired LVEF from SP1049C and prior
anthracycline therapy was considered to have contributed to the
death.
Gastrointestinal At doses of 420mgm
 2, anorexia, nausea and
vomiting were observed although grade 3 or 4 gastrointestinal
toxicity was uncommon. Nausea and vomiting responded well to
standard antiemetics. Grade 1–3 stomatitis was experienced by 12
(46%) of patients at dose levels 35–90mgm
 2, with grade 3 only at
the highest two dose levels. At dose levels of 35mgm
 2 and above,
treatment-related fatigue and alopecia were seen.
Efficacy
A total of 21 patients (81%) were evaluable for response. No
patients had a complete or partial response. One patient with
oesophageal carcinoma and liver metastases (previous progression
on three cycles of cisplatin 80mgm
 2 þ5 fluorouracil 1gm
 2
days 1–4) treated at 70mgm
 2 had a rapid symptomatic improve-
ment in tumour-related dysphagia and pain. During treatment,
tumour shrinkage occurred and the CT scan after six cycles
showed a partial response, with a complete response in the liver
metastases. However, the response was not confirmed 4 weeks
later. A second patient with Ewing’s sarcoma and lung metastases
(previous doxorubicin-containing IVAD with partial response)
was treated with 35mgm
 2 for five cycles. A chest X-ray indicated
a partial response after five cycles, but the patient declined follow-
up and the partial response could not therefore be confirmed. A
third patient with carcinosarcoma of the uterus, ovary and
peritoneum (previous progression with both carboplatin single
agent and carboplatin-ifosfamide) was treated with SP1049C at
35mgm
 2 and had a 28% reduction in measurable disease and a
50% reduction in CA125 level. However, after six cycles of
SP1049C, both the tumour dimensions and CA125 had increased
slightly. Eight (31%) patients had stable disease with a median time
to progression of 17.5 weeks (range 9–24 weeks). A total of 13
(50%) patients had progressive disease. At the time of analysis,
54% of the patients had died. Two of these occurred within 4 weeks
of the drug being administered. One patient with oesophageal
carcinoma and liver metastases received one cycle of SP1049C at
35mgm
 2 but developed total dysphagia 12 days after this and
subsequently died of progressive disease. A second patient with
adenocarcinoma of the lung received one cycle of SP1049C at
70mgm
 2 and 4 days afterwards died of progressive disease.
Pharmacokinetics
In all, 25 (96%) patients were evaluable for pharmacokinetics. One
patient had poor venous access precluding sampling. The plasma
pharmacokinetic profile of SP1049C was best described by a three-
compartment model with an initial ‘distributional’ phase (mean
half-life of 6.6min), an intermediate phase (mean half-life of
2.83h) and an ‘elimination’ phase (mean half-life 48.8h) (Table 4).
These values are similar to those reported for conventional
doxorubicin although the terminal half-life for conventional
doxorubicin in most reports has been shorter at circa 30h
(Eksborg, 1989). The AUC(0–N) of doxorubicin following SP1049C
increased linearly (r
2¼0.71) with increasing dose for the dose
range of the study (Figure 2).
DISCUSSION
Several approaches have been used to try to improve the
therapeutic efficacy and toxicity profile of doxorubicin including
the development of anthracycline analogues and the incorporation
of anthracyclines into drug delivery vehicles. Liposomal drug
delivery systems with doxorubicin have been extensively investi-
gated in relapsed ovarian cancer (Muggia et al, 1997), breast
cancer (Ranson et al, 1997) and others (Law et al, 1994; Schwartz
and Caspar, 1995; Ellerhorst et al, 1999; Harrington et al, 2001;
Judson et al, 2001). A number of trials have been performed with
polymer–doxorubicin conjugate where there is covalent linkage of
polymer to doxorubicin. Initial clinical experience of PK1, a
covalent doxorubicin–polymer conjugate, demonstrated anti-
cancer activity and a reduction in doxorubicin dose-limiting
toxicities (Vasey et al, 1999).
Table 4 Plasma pharmacokinetics of SP1049C doxorubicin
Patient number Dose (mgm
 2) Dose (mg) AUC (hlgml
 1) Vc (l) Cl (lh
 1) T1/2 a (h) T1/2 b (h) T1/2 c (h)
1 5 10.2 0.10 1.27 0.60 0.110 2.02 25.20
2 10 17.0 0.16 1.81 0.46 0.073 1.76 NA
3 20 33.0 0.38 12.20 84.2 0.083 0.25 31.10
4 35 50.0 2.19 22.70 34.4 0.114 1.96 65.50
6 35 53.0 2.02 26.40 30.2 0.160 3.15 68.00
7 35 55.0 1.44 36.90 40.8 0.157 4.76 59.10
8 35 77.0 1.13 56.90 81.4 0.162 9.55 97.00
9 35 66.0 2.15 35.20 33.1 0.142 6.82 98.70
10 35 60.0 1.37 8.48 41.7 0.071 0.83 25.90
11 50 108.0 2.19 12.70 44.5 0.073 0.69 27.10
12 50 84.0 1.58 55.60 48.6 0.129 1.89 64.10
13 50 121.5 1.65 15.10 63.3 0.069 3.88 47.60
14 50 85.0 2.16 8.51 34.9 0.065 0.89 25.40
15 50 95.0 1.54 50.40 78.7 0.176 6.05 102.00
16 50 95.0 1.93 10.60 47.3 0.084 1.24 35.20
17 70 140.0 4.08 35.90 65.2 0.132 1.07 42.00
18 70 120.0 3.21 10.80 37.7 0.086 2.96 31.50
19 70 134.0 4.20 5.85 29.0 0.089 2.79 31.00
20 70 123.0 2.19 25.00 67.1 0.093 3.05 32.70
21 90 167.0 3.70 39.30 56.4 0.183 4.94 65.50
22 90 185.0 2.91 8.04 46.2 0.062 0.73 22.30
23 90 189.0 4.29 45.40 56.8 0.105 2.96 49.50
24 70 125.0 1.62 18.30 71.4 0.089 1.73 21.30
25 70 154.0 2.95 49.40 87.4 0.108 2.83 39.20
26 70 120.0 2.09 24.10 56.8 0.082 1.91 56.50
AUC¼area under the curves; Vc¼Volume (central); Cl¼Clearance.
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lFor the covalently linked polymer formulation of doxorubicin,
PK1 (mw 30000), the phase I trial MTD of 320mgm
 2 on a 3
weekly regimen is much higher than that for doxorubicin or for
SP1049C (Vasey et al, 1999). This was predicted by preclinical
toxicology of PK1 which demonstrated an rodent LD10 of
approximately 150mgm
 2 (Duncan et al, 1998) compared to circa
50mgm
 2 for doxorubicin and SP1049C (Alakhov et al, 1999). For
the liposomal doxorubicin formulation TLC D-99, the MTD in
preclinical toxicology in rodents of approximately 100mgm
 2
translated well into the clinic where a clinical MTD of 75–
90mgm
 2 was seen (Lohri et al, 1991; Cowens et al, 1993; Swenson
et al, 1998). The clinical use of a pegylated liposomal formulation
of doxorubicin (Caelyx/Doxil) was associated with dose-limiting
palmar plantar erythrodysthesia when administered at 3 weekly
dosing at X45mgm
 2 (Ranson et al, 1997). This cutaneous
toxicity was seen during preclinical evaluation but was not fully
predicted by short-term toxicology studies (Working, 1998).
SP1049C is a distinct and novel approach in which doxorubicin
is incorporated into micelles with two nonionic copolymers,
Pluronic L61 and Pluronic F127. Of particular note is the evidence
of antitumour activity of SP1049C in doxorubicin-resistant
tumours (Batrakova et al, 1996) and in multiple drug resistance
(MDR) cells (Venne et al, 1996; Alakhov et al, 1999). There appear
to be several potential mechanisms, including inhibition of drug
efflux transporters, abolishment of drug sequestration in acidic
compartments, inhibition of the glutathione (GSH)/glutathione
(GST) detoxification system and reduction of ATP selectively in
MDR cells (Venne et al, 1996; Batrakova et al, 2001; Kabanov et al,
2002). In preclinical models, in vivo SP1049C was found to be
superior to convential doxorubicin in all nine models tested.
This is the first phase I study with SP1049C. SP1049C
was evaluated at seven dose levels between 5–90mgm
 2 (all
doses expressed as doxorubicin equivalent). Single patient cohorts
were evaluated at 5, 10 and 20mgm
 2 and these dose levels were
not associated with any significant drug-related toxicity. SP1049C
exhibited a predictable toxicity spectrum in line with other
anthracyclines at doses of 35mgm
 2 and above. Dose-related
myelosuppression was seen and DLT (neutropenic sepsis) was
reached at 90mgm
 2. The MTD of SP1049C defined in this study
was 70mgm
 2. Neutropenia occurred with a nadir between day 8
and 15 post dose, with recovery to baseline levels by day 22.
Thrombocytopenia was less pronounced and not dose limiting. As
is common with cytotoxic chemotherapy in patients with advanced
cancer who have received prior therapy, mild anaemia was common.
Nonhaematological toxicity included transient lethargy (similar to
that seen with other cytotoxic chemotherapeutic agents in patients
with advanced cancer), stomatitis and reversible alopecia. No skin
toxicity or palmar plantar erythrodysthesia was seen. Nausea and
vomiting was easily controlled with standard antiemetics.
Given the activity of SP1049C in anthracycline-resistant tumours
in animal models, the design of this trial allowed patients to have
received prior anthracycline therapy. It was required that patients
have a baseline LVEF of 55% or more and that they have LVEF
reassessments during therapy. Four patients, three of whom had
received prior anthracyclines, had a fall in LVEF of CTC Grade 2
during SP1049C. In three cases, no clinical signs of cardiac
decompensation or cardiac failure were encountered. However, in
one patient the fall in cardiac ejection fraction was felt to
contribute to death during an episode of sepsis after trial
completion. The cardiac safety of SP1049C cannot be accurately
delineated in a phase I study such as this because of the small
number of patients studied, the marked hetererogeneity in prior
treatment and the variable extent of SP1049C exposure. There
remains a need for the monitoring of cardiac safety during phase II
and III trials. The pharmacokinetic profile was similar to that
described previously with conventional doxorubicin but with a
slower terminal clearance.
Evidence of antitumour activity following SP1049C was seen in
several patients with advanced solid tumours (Ewing’s sarcoma,
carcinosarcoma, and oesophageal adenocarcinoma). These three
patients had received prior therapy to which one patient had
responded but the other two had not. Given the promising
preclinical data in anthracycline-resistant tumour settings and the
data from this phase I trial, phase II trials of SP1049C at 70mgm
 2
in selected advanced cancers are now required to further define its
antitumour efficacy and safety in larger cohorts of patients. Phase
II trials are currently underway in metastatic oesophageal
carcinoma and soft-tissue sarcoma.
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